^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    FNDC1 (Fibronectin Type III Domain Containing 1)

    i
    Other names: FNDC1, Fibronectin Type III Domain Containing 1, BA243O10.1, DJ322A24.1, KIAA1866, FNDC2, Fibronectin Type III Domain-Containing Protein 1, Fibronectin Type III Domain Containing 2, Expressed In Synovial Lining Protein, Activation-Associated CDNA Protein, MEL4B3, AGS8
    11d
    Pan-cancer analysis reveals ELFN1 as a novel prognostic biomarker and immunotherapeutic target associated with tumor microenvironment remodeling and promoting malignant phenotypes in colorectal cancer. (PubMed, Front Oncol)
    Furthermore, Drug sensitivity profiling linked ELFN1 to ABT-737 susceptibility and benzaldehyde resistance through molecular docking. In CRC cells, ELFN1 knockdown significantly inhibited tumor proliferation, migration, and motility. The expression level of ELFN1 may provide insights into tumor development and progression in multiple cancers, including CRC, highlighting its potential utility as an effective prognostic biomarkers and immunotherapeutic targets.
    Journal • IO biomarker • Pan tumor
    |
    FNDC1 (Fibronectin Type III Domain Containing 1)
    |
    ABT-737
    2ms
    Analysis of FNDC1 as a diagnostic marker and potential therapeutic target for ovarian serous cancer. (PubMed, BMC Cancer)
    FNDC1 was a potential diagnostic marker, prognostic indicator, and target for the treatment of ovarian serous cancer.
    Journal
    |
    FNDC1 (Fibronectin Type III Domain Containing 1) • TNFSF4 (TNF Superfamily Member 4)
    2ms
    Comparative analysis reveals recurrent molecular alterations in low-risk HPV6 and HPV11-associated squamous cell carcinoma of the uterine cervix and vulva. (PubMed, Mod Pathol)
    We provide evidence that SCCs associated with low-risk HPV are distinct entities, differing from those related to high-risk HPV and more closely resembling HPV-independent neoplasms. Given that low-risk HPV-associated SCCs of the cervix and vulva exhibit unique morphological and molecular features, they should either be described separately within existing classification systems or classified as a distinct new entity.
    Journal
    |
    TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • FGFR2 (Fibroblast growth factor receptor 2) • HRAS (Harvey rat sarcoma viral oncogene homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • ARID1A (AT-rich interaction domain 1A) • NOTCH1 (Notch 1) • TERT (Telomerase Reverse Transcriptase) • ASXL1 (ASXL Transcriptional Regulator 1) • ATRX (ATRX Chromatin Remodeler) • TSC2 (TSC complex subunit 2) • NOTCH2 (Notch 2) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • CARD11 (Caspase Recruitment Domain Family Member 11) • NOTCH3 (Notch Receptor 3) • STAG2 (Stromal Antigen 2) • KMT2B (Lysine Methyltransferase 2B) • EPHA5 (EPH Receptor A5) • FNDC1 (Fibronectin Type III Domain Containing 1) • BCORL1 (BCL6 Corepressor Like 1)
    |
    ARID1A mutation • FGFR2 mutation
    6ms
    The prognostic and immune significance of fibronectin type III domain-containing 1 gene in pan-cancer and its relationship with proliferation and migration of stomach adenocarcinoma. (PubMed, Transl Cancer Res)
    FNDC1 is highly expressed in various tumor tissues and may serve as a potential prognostic biomarker and immunotherapy target in cancer. It plays a crucial role in proliferation, migration and invasion of STAD.
    Journal • BRCA Biomarker • IO biomarker • Pan tumor
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA (Breast cancer early onset) • PD-L2 (Programmed Cell Death 1 Ligand 2) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • GNAS (GNAS Complex Locus) • COL3A1 (Collagen Type III Alpha 1 Chain) • FNDC1 (Fibronectin Type III Domain Containing 1) • SFRP4 (Secreted frizzled-related protein 4)
    |
    HER-2 expression
    7ms
    Atf3 + senescent chondrocytes mediate meniscus degeneration in aging. (PubMed, Arthritis Res Ther)
    We identified Atf3 + senescent chondrocytes as a key pathogenic population in the aging meniscus, driving degeneration via the ANGPTL4 pathway. Targeting Atf3 + cells or ANGPTL4 signaling may offer new therapeutic strategies for age-related meniscus degeneration and arthritis.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TNFA (Tumor Necrosis Factor-Alpha) • SDC4 (Syndecan 4) • SOX9 (SRY-Box Transcription Factor 9) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • FNDC1 (Fibronectin Type III Domain Containing 1) • ANGPTL4 (Angiopoietin Like 4) • ATF3 (Activating Transcription Factor 3)
    1year
    FNDC1 Facilitates Proliferation, Migration, and Invasion of Breast Cancer Cells Through Modulating Wnt/β-Catenin Pathway. (PubMed, Biochem Genet)
    Notably, Wnt/β-catenin activation with LiCl significantly enhanced the proliferation and epithelial-mesenchymal transformation (EMT) inhibition effect of silencing FNDC1, whereas Wnt/β-catenin inhibition with XAV-939 significantly weakened the proliferation and EMT promotion effect of FNDC1...These data suggested that FNDC1 exerts its oncogene function through modulating Wnt/β-catenin signaling pathway. In conclusion, FNDC1 promotes cell proliferation, migration, invasion, and EMT through modulating Wnt/β-catenin signaling pathway in breast cancer, providing a new idea for the development of breast cancer therapeutic targets.
    Journal
    |
    MKI67 (Marker of proliferation Ki-67) • FNDC1 (Fibronectin Type III Domain Containing 1)
    |
    XAV-939
    over1year
    Molecular Responses of the Eukaryotic Cell Line INT407 on the Internalized Campylobacter jejuni-The Other Side of the Coin. (PubMed, Pathogens)
    The seemingly balanced status quo between the invader and the host is the result of a complex process that also affects genes known to be associated with postinfectious pathological conditions. The upregulation of TLR3 (3.79×) and CD36 (2.73×), two general tumor markers, and SERPINEB9 (11.37×), FNDC1 (7.58×), and TACR2 (8.84×), three factors of tumorigenesis, confirms the wider pathological significance of this bacterium.
    Preclinical • Journal
    |
    CD36 (thrombospondin receptor) • TLR3 (Toll Like Receptor 3) • FNDC1 (Fibronectin Type III Domain Containing 1)
    over1year
    Investigation of the pan-cancer property of FNDC1 and its molecular mechanism to promote lung adenocarcinoma metastasis. (PubMed, Transl Oncol)
    FNDC1 is implicated in poor prognosis of a diverse range of malignant tumors, which can promote metastasis and invasion of lung cancer through the JAK2-STAT3 signaling pathway.
    Journal • Pan tumor
    |
    MMP2 (Matrix metallopeptidase 2) • FNDC1 (Fibronectin Type III Domain Containing 1)
    over2years
    Inhibition of FNDC1 suppresses gastric cancer progression by interfering with Gβγ-VEGFR2 complex formation. (PubMed, iScience)
    In this study, we demonstrated that arsenite can efficiently suppress FNDC1 expression, attenuating the formation of the trimers and downstream pathways. Altogether, our results indicate that FNDC1 might be a promising target for clinical treatment and prognostic judgment, while FNDC1 inhibition by arsenite provides a new opportunity for overcoming this fatal disease.
    Journal
    |
    KDR (Kinase insert domain receptor) • TWIST1 (Twist Family BHLH Transcription Factor 1) • FNDC1 (Fibronectin Type III Domain Containing 1)
    |
    FNDC1 overexpression
    over2years
    Immune-Related Long Non-Coding RNA Signatures for Tongue Squamous Cell Carcinoma. (PubMed, Curr Oncol)
    A prognostic model based on six immune-related signature lncRNAs was established. This six-lncRNA prognostic model has clinical significance and may be helpful in the development of personalized immunotherapy strategies.
    Journal • IO biomarker
    |
    FNDC1 (Fibronectin Type III Domain Containing 1) • NAALADL2-AS2 (NAALADL2 Antisense RNA 2)
    over2years
    LncRNA ELFN1-AS1 upregulates TRIM29 by suppressing miR-211-3p to promote gastric cancer progression. (PubMed, Acta Biochim Biophys Sin (Shanghai))
    Rescue experiments reveal that the oncogenicity of ELFN1-AS1 is modulated by acting as a sponge for miR-211-3p, thereby increasing the expression of the target gene of miR-211-3p, TRIM29. In summary, ELFN1-AS1 maintains GC cell tumorigenicity via the ELFN1-AS1/miR-211-3p/TRIM29 axis, indicating that this axis can be directed for GC treatment in the future.
    Journal
    |
    MIR211 (MicroRNA 211) • FNDC1 (Fibronectin Type III Domain Containing 1)
    over2years
    The role of miR-143-3p/FNDC1 axis on the progression of non-small cell lung cancer. (PubMed, Eur J Histochem)
    In conclusion, FNDC1 promotes the malignant prototypes of NSCLC cells. miR-143-3p is a negative regulator of FNDC1 in NSCLC cells, which may serve as a promising therapeutic target in NSCLC.
    Journal
    |
    FNDC1 (Fibronectin Type III Domain Containing 1) • MIR143 (MicroRNA 143)
    |
    FNDC1 overexpression • miR-143-3p overexpression